Cargando…

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma

BACKGROUND: We assessed the surrogacy of objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) for overall survival (OS) in anti-PD-1/PD-L1 trials of metastatic melanoma through a meta-analysis of randomized controlled trials (RCTs). METHODS: PubMed and EMBASE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Run-Cong, Yuan, Shu-Qiang, Wang, Yun, Zou, Xue-Bin, Chen, Shi, Li, Shu-Man, Duan, Jin-Ling, Zhou, Jie, Chen, Guo-Ming, Luo, Tian-Qi, Zhou, Zhi-Wei, Li, Yuan-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301660/ https://www.ncbi.nlm.nih.gov/pubmed/32595775 http://dx.doi.org/10.1177/1758835920929583

Ejemplares similares

Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects
por: Zhang, Wenjing, et al.
Publicado: (2021)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients’ data
por: Huan, Hong-Bo, et al.
Publicado: (2017)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
por: Cremolini, Chiara, et al.
Publicado: (2017)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis
por: Geng, Zhe, et al.
Publicado: (2018)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
por: Liu, Gang, et al.
Publicado: (2021)

Meta-analysis of the prognostic value of lncRNA ZFAS1 in patients with solid tumors
por: Song, Wei, et al.
Publicado: (2017)

Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis
por: He, Xiao-Yuan, et al.
Publicado: (2023)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature
por: TSIOGKA, Aikaterini, et al.
Publicado: (2021)

Predictive role of C-reactive protein in sudden death: a meta-analysis of prospective studies
por: Zhou, Ruhua, et al.
Publicado: (2022)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
por: Gill, Amanda L., et al.
Publicado: (2016)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

Meta-analysis of SIRT1 expression as a prognostic marker for overall survival in gastrointestinal cancer
por: Wu, Shuangjie, et al.
Publicado: (2017)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial
por: Zhao, Li-Min, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

Prognostic significance of anti-diabetic medications in pancreatic cancer: A meta-analysis
por: Zhou, Dong-Chu, et al.
Publicado: (2017)

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
por: Homet Moreno, B, et al.
Publicado: (2015)

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
por: Jiang, Qi, et al.
Publicado: (2017)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis
por: Huang, Qi, et al.
Publicado: (2017)

Impact of enhanced recovery after surgery programs on pancreatic surgery: A meta-analysis
por: Ji, Hai-Bin, et al.
Publicado: (2018)

Associations between dietary folate intake and risks of esophageal, gastric and pancreatic cancers: an overall and dose-response meta-analysis
por: Liu, Wen, et al.
Publicado: (2017)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

The anti-inflammatory and haemodynamic effects of levosimendan on advanced heart failure patients: a meta-analysis of published studies
por: Zhou, Suzhen, et al.
Publicado: (2023)

Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer
por: Chitapanarux, Taned, et al.
Publicado: (2023)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Association between nonsteroidal anti-inflammatory drugs use and risk of central nervous system tumors: a dose-response meta analysis
por: Zhang, Tao, et al.
Publicado: (2017)

Tobacco smoking and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies
por: Aune, Dagfinn, et al.
Publicado: (2018)

Diagnostic value of WIF1 methylation for colorectal cancer: a meta-analysis
por: Hu, Haochang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_077j29qvt3bi8onsv9h8sd9dic